Global Healthcare Nanomedicine Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Healthcare Nanomedicine Market Insights, Forecast to 2034
Healthcare nanomedicine refers to the application of nanotechnology in the field of medicine and healthcare. Nanotechnology involves manipulating materials at the nanoscale, typically at the level of atoms and molecules, to create structures and devices with unique properties and capabilities. When applied to healthcare, nanomedicine offers promising solutions for disease diagnosis, treatment, and prevention.
Market Analysis and InsightsGlobal Healthcare Nanomedicine Market
Global Healthcare Nanomedicine market is expected to reach to US$ 221450 million in 2024, with a positive growth of %, compared with US$ 201240 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Healthcare Nanomedicine industry is evaluated to reach US$ 392310 million in 2029. The CAGR will be 10.0% during 2024 to 2029.
Globally, Healthcare Nanomedicine key companies include Amgen, Teva Pharmaceuticals, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen and Gilead Sciences, etc. Amgen, Teva Pharmaceuticals, UCB are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Healthcare Nanomedicine were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Healthcare Nanomedicine market and estimated to attract more attentions from industry insiders and investors.
Healthcare Nanomedicine can be divided into Nanoparticle Drug and Nanocarrier Drug, etc. Nanoparticle Drug is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Healthcare Nanomedicine is widely used in various fields, such as Anticancer, CNS Product, Anti-infective and Other, etc. Anticancer provides greatest supports to the Healthcare Nanomedicine industry development. In 2022, global % revenue of Healthcare Nanomedicine went into Anticancer filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Healthcare Nanomedicine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Healthcare Nanomedicine market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Amgen
Teva Pharmaceuticals
UCB
Roche
Celgene
Sanofi
Merck & Co
Biogen
Gilead Sciences
Pfizer
Leadiant Biosciences
Kyowa Hakko Kirin
Takeda
Ipsen
Endo International
Segment by Type
Nanoparticle Drug
Nanocarrier Drug
Anticancer
CNS Product
Anti-infective
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Healthcare Nanomedicine introduction, etc. Healthcare Nanomedicine Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Healthcare Nanomedicine
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Healthcare Nanomedicine Market
Global Healthcare Nanomedicine market is expected to reach to US$ 221450 million in 2024, with a positive growth of %, compared with US$ 201240 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Healthcare Nanomedicine industry is evaluated to reach US$ 392310 million in 2029. The CAGR will be 10.0% during 2024 to 2029.
Globally, Healthcare Nanomedicine key companies include Amgen, Teva Pharmaceuticals, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen and Gilead Sciences, etc. Amgen, Teva Pharmaceuticals, UCB are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Healthcare Nanomedicine were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Healthcare Nanomedicine market and estimated to attract more attentions from industry insiders and investors.
Healthcare Nanomedicine can be divided into Nanoparticle Drug and Nanocarrier Drug, etc. Nanoparticle Drug is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Healthcare Nanomedicine is widely used in various fields, such as Anticancer, CNS Product, Anti-infective and Other, etc. Anticancer provides greatest supports to the Healthcare Nanomedicine industry development. In 2022, global % revenue of Healthcare Nanomedicine went into Anticancer filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Healthcare Nanomedicine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Healthcare Nanomedicine market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen
Teva Pharmaceuticals
UCB
Roche
Celgene
Sanofi
Merck & Co
Biogen
Gilead Sciences
Pfizer
Leadiant Biosciences
Kyowa Hakko Kirin
Takeda
Ipsen
Endo International
Segment by Type
Nanoparticle Drug
Nanocarrier Drug
Segment by Application
Anticancer
CNS Product
Anti-infective
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Healthcare Nanomedicine introduction, etc. Healthcare Nanomedicine Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Healthcare Nanomedicine
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices